Celldex's Phase Three CSU Data Will Either Justify the Mast Cell Biology Bet or Expose It

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

CLDX typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around CLDX earnings shows significant volatility with an average absolute Day 0 move of 5.59% and Day +1 move of 3.11%. The most dramatic reaction came in February 2026, when shares surged 24.07% on Day 0—likely driven by positive clinical news or pipeline updates accompanying the earnings release.

The pattern reveals considerable unpredictability in direction. While some reports triggered sharp rallies (November 2025's +7.50% Day +1 move, May 2025's +3.23% Day 0 move), others produced notable declines (May 2025's -6.10% Day +1 drop, November 2024's -4.20% Day +1 decline). The average Day 0 range of 8.93% and Day +1 range of 7.28% indicate substantial intraday swings regardless of ultimate direction.

Investors should prepare for meaningful volatility, with moves frequently exceeding 5% in either direction as the market digests not just the financial results but—more importantly for a clinical-stage biotech—any pipeline updates, trial data, or regulatory developments disclosed alongside the earnings.

Part 3: What Analysts Are Saying

Analyst sentiment on CLDX is overwhelmingly bullish heading into earnings. The consensus rating stands at 4.76 out of 5.0, with 15 of 17 analysts rating the stock a Strong Buy, while only 2 maintain Hold ratings. Notably, there are zero Sell or Strong Sell recommendations, reflecting broad confidence in the company's clinical pipeline despite near-term losses.

The average price target of $57.80 implies 41% upside from the current price of $41.06, suggesting analysts believe the market is undervaluing CLDX's development programs. However, the wide dispersion in targets—ranging from a low of $34.00 to a high of $100.00—highlights the binary nature of clinical-stage biotech investing, where outcomes hinge on trial results and regulatory decisions.

Analyst sentiment has remained unchanged over the past month, with the rating distribution holding steady at 15 Strong Buys and 2 Holds. This stability suggests the Street is maintaining conviction in its bullish thesis despite the company's recent pattern of earnings misses. The lack of downgrades indicates analysts view the widening losses as an expected consequence of advancing multiple clinical programs rather than a fundamental concern about the business model.

Part 4: Technical Picture

CLDX enters earnings with exceptionally strong technical momentum. The Barchart Technical Opinion currently registers 100% Buy, unchanged from both one week ago and one month ago, indicating sustained bullish conviction across all timeframes.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates powerful near-term momentum as the stock approaches earnings
• Medium-term (100% Buy): Continued strength in the intermediate timeframe reflects a well-established uptrend
• Long-term (100% Buy): Maximum bullish reading suggests the longer-term trend remains firmly positive

The trend is ranked in the Top 1% with the Strongest directional momentum, an exceptional setup that reflects powerful buying pressure across all time horizons heading into the earnings event.

The stock is trading above all key moving averages, demonstrating broad-based technical strength. CLDX currently sits above its 5-day ($38.87), 10-day ($37.38), 20-day ($37.17), 50-day ($34.62), 100-day ($33.35), and 200-day ($29.84) moving averages. The sequential alignment with each average progressively lower illustrates a textbook uptrend structure.

The 38% premium to the 200-day moving average represents significant extension, suggesting the stock has priced in considerable optimism about clinical progress. While the uniformly bullish technical picture provides support, the magnitude of the advance creates vulnerability to disappointment. Any setback in clinical timelines or worse-than-expected cash burn could trigger profit-taking from an overbought technical position. Conversely, positive pipeline news could extend the breakout given the strong momentum backdrop and overwhelming analyst support.